Letter to the editor
We read with interest the Pappas et al review on postprandial dysmetabolism. 1 The authors describe evidence linking elevated levels of postprandial glucose and triglycerides (TGs) with cardiovascular (CV) morbidity and mortality as well as with polycystic ovary syndrome (PCOS), non-alcoholic fatty liver disease (NAFLD) and lack of hepatic receptors such as low density lipoprotein receptor (LDLR).
1 Specifically, it was reported that subjects with familial hypercholesterolemia have exaggerated and prolonged response to fatty meal loading. 2 The authors also discuss methods for screening and diagnosis of postprandial dysmetabolism as well as therapeutic options including lifestyle modifications, antidiabetic and hypolipidemic drugs.
The lack of a widely approved standardized protocol for the assessment of postprandial lipemia (PPL) impedes the early diagnosis and adequate treatment of this metabolic disorder. 3 In this context, a previous meta-analysis proposeda 4 h time-point following an oral fat test meal containing 70-79 g of fat as the most representative method to measure PPL. 4 Pappas et al. 1 mention the cut-off point of 175 mg/ dl for non-fasting TGs as suggested by White et al 5 in a sub-population of the Women's Health Study. An expert panel statement had earlier discussed the clinical implications and assessment of PPL proposing as optimal non-fasting TGs <180 mg/dl (2 dl (2.5 mmol/l) at any time following a fat tolerance test (given after 8 h of fasting and consisting of 75 g fat, 25 g carbohydrates and 10 g protein). 6 The same expert panel recommended that a fat tolerance test should be performed in individuals with non-fasting TGs 89-180 md/dl (1-2 mmol/l).
Antidiabetic and hypolipidemic drugs have been reported to improve postprandial dysmetabolism as mentioned by Pappas et al. 1 Statins and insulinsensitizer drugs (i.e. metformin and pioglitazone) were also shown to beneficially affect metabolic and menstrual abnormalities in PCOS. 7 Moreover, it was found that gut peptides such as glucagon-like peptide-1 (GLP-1) and GLP-2 could be involved in homeostasis of PPL. Thus, the GLP-1 receptor agonists (GLP-1 RA) may be able to improve metabolic features in PCOS women but further research is needed in this field. 8 With regard to NAFLD, statins and antidiabetic drugs [e.g. pioglitazone, dipeptidyl peptidase-4 (DPP-4) inhibitors, GLP-1 RA and sodium-glucose co-transporter 2 (SGLT2) inhibitors] are also likely to improve biochemical and/or histological features of NAFLD and its advanced form i.e. non-alcoholic steatohepatitis (NASH). [9] [10] [11] [12] [13] Overall, combination therapy with both antidiabetic and hypolipidemic drugs may be a useful therapeutic tool for patients with postprandial dysmetabolism and PCOS or NAFLD. [14] [15] [16] Nevertheless, further investigations are required to firmly establish such associations.
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